IgG-monoclonal antibody that targets leukemic cells receptors. Use for Esclerosis Multiple has been approved.
Because a high molecular weight excretion into breast milk is unlikely and destruction of protein structure in infant's bowel renders intestinal absorption nil.
It should be avoid in the first two post-partum weeks since pass of significant amounts of IgG to the milk can occur in the first 3 - 4 post-partum days.
We do not have alternatives for Alemtuzumab.
Very Low Risk
Compatible. Not risky for breastfeeding or infant.
Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.
Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.
Very High Risk
Not recommended. Cessation of breastfeeding or alternative.
- Almas S, Vance J, Baker T, Hale T. Management of Multiple Sclerosis in the Breastfeeding Mother. Mult Scler Int. 2016Abstract Full text (link to original source) Full text (in our servers)
- Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler. 2013Abstract Full text (link to original source) Full text (in our servers)
- Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman S, Hillmen P, Brettman LR, Reif S, Bonate PL. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol. 2007Abstract Full text (link to original source)